The Deloitte Consulting partner discusses how GLP-1s are becoming key value drivers and driving R&D focus during a period of market concentration.
Kevin Dondarski
Advertisement
Kevin Dondarski is a partner at Deloitte Consulting, life sciences strategy practice.
Articles by Kevin Dondarski
Kevin Dondarskit of Deloitte Consulting discusses the risks that drug makers face if they decide to put too much focus on an area where they may lack expertise, such as the emerging GLP-1 market.
Kevin Dondarskit of Deloitte Consulting discusses how pharma companies are focusing on high-value assets that serve large patient populations.
Kevin Dondarski from Deloitte Consulting discusses how changes in industry trends are causing pharma companies to explore new market opportunities provided by the rise of GLP-1 medications.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
2
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
3
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
4
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
5